Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

Autor: Christoffer Bundgaard, Ligia Westrich, Arne Mørk, Benny Bang-Andersen, T. Bryan Stensbøl, Christina W. Fischer, Samuel I. Miller, Sandra Hogg, Nico Liebenberg, Gregers Wegener, Alan L. Pehrson, Connie Sanchez, H. Zhong, Lise T. Brennum, A.B. Lassen, N. J. Boyle, S. Møller Nielsen

Publikováno v: Mork, A, Pehrson, A, Tottrup Brennum, L, Moller Nielsen, S, Zhong, H, Lassen, A B, Miller, S, Westrich, L, Boyle, N J, Sanchez, C, Fischer, C, Liebenberg, N, Wegener, G, Bundgaard, C, Hogg, S, Bang-Andersen, B & Bryan Stensbol, T 2012, ' Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder ', Journal of Pharmacology and Experimental Therapeutics, vol. 340, no. 3, pp. 666-675 . https://doi.org/10.1124/jpet.111.189068

1-[2-(2,4-Dimethylphenyl-sulfanyl)-phenyl]-piperazine (Lu AA21004) is a human (h) serotonin (5-HT)(3A) receptor antagonist (K(i) = 3.7 nM), h5-HT(7) receptor antagonist (K(i) = 19 nM), h5-HT(1B) receptor partial agonist (K(i) = 33 nM), h5-HT(1A) rece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::723937f4dcc13fe06f59dd1b3127c678
https://doi.org/10.1124/jpet.111.189068